Association between metabolic overweight/obesity phenotypes and readmission risk in patients with lung cancer: A retrospective cohort study
- PMID: 35898319
- PMCID: PMC9310118
- DOI: 10.1016/j.eclinm.2022.101577
Association between metabolic overweight/obesity phenotypes and readmission risk in patients with lung cancer: A retrospective cohort study
Abstract
Background: Increased body mass index (BMI) and metabolic abnormalities are controversial prognostic factors of lung cancer. However, the relationship between metabolic overweight/obesity phenotypes and hospital readmission in patients with lung cancer is rarely reported.
Methods: We established a retrospective cohort using the United States (US) Nationwide Readmissions Database (NRD). We included adult patients diagnosed with lung cancer from January 1, 2018 to November 30, 2018 and excluded patients combined with other cancers, pregnancy, died during hospitalization, low body weight, and those with missing data. The cohort was observed for hospital readmission until December 31, 2018. We defined and distinguished four metabolic overweight/obesity phenotypes: metabolically healthy with normal weight (MHNW), metabolically unhealthy with normal weight (MUNW), metabolically healthy with overweight or obesity (MHO), and metabolically unhealthy with overweight or obesity (MUO). The relationship between metabolic overweight/obesity phenotypes and 30-day readmission risk was assessed by multivariable Cox regression analysis.
Findings: Of the 115,393 patients included from the NRD 2018 (MHNW [58214, 50.4%], MUNW [44980, 39.0%], MHO [5044, 4.4%], and MUO [7155, 6.2%]), patients with the phenotype MUNW (6531, 14.5%), MHO (771, 15.3%), and MUO (1155, 16.1%) had a higher readmission rate compared to those with MHNW (7901, 13.6%). Compared with patients with the MHNW phenotype, those with the MUNW (hazard ratio [HR], 1.10; 95% CI, 1.06-1.14), MHO (HR, 1.15; 95% CI, 1.07-1.24), and MUO (HR, 1.28; 95% CI, 1.20-1.36) phenotypes had a higher risk of readmission, especially in men, those without surgical intervention, or those aged >60 years. In women, similar results with respect to readmission were observed in people aged >60 years (MUNW [HR, 1.07; 95% CI, 1.01-1.13], MHO [HR, 1.19; 95% CI, 1.06-1.35], and MUO [HR, 1.28; 95% CI, 1.16-1.41]). We also found increased costs for 30-day readmission in patients with MHO (OR, 1.18; 95% CI, 1.07-1.29) and MUO (OR, 1.11; 95% CI, 1.02-1.20).
Interpretation: Increased BMI and metabolic abnormalities are independently associated with higher readmission risks in patients with lung cancer, whereas increased BMI also increases the readmission costs. Follow-up and intervention method targeting increased BMI and metabolic abnormalities should be considered for patients with lung cancer.
Funding: The National Key Research and Development Program of China (2017YFC1309800).
Keywords: BMI, body mass index; Body mass index; CI, confidence interval; HCUP, Healthcare Cost and Utilization Project; HR, hazard ratio; ICD-10, International Classification of Diseases, 10th Revision; LOS, length of stay; Lung cancer; MHNW, metabolically healthy with normal weight; MHO, metabolically healthy with overweight or obesity; MS, metabolic syndrome; MUNW, metabolically unhealthy with normal weight; MUO, metabolically unhealthy with overweight or obesity; Metabolic abnormality; NRD, Nationwide Readmissions Database; OR, odds ratio; PCS, Procedure Coding System; Phenotype; Readmission.
© 2022 The Author(s).
Conflict of interest statement
All authors declare no competing interests.
Figures


Similar articles
-
Transition patterns of metabolism-weight phenotypes over time: A longitudinal study using the multistate Markov model in China.Front Public Health. 2022 Dec 15;10:1026751. doi: 10.3389/fpubh.2022.1026751. eCollection 2022. Front Public Health. 2022. PMID: 36589938 Free PMC article.
-
Association between different metabolic phenotypes of obesity and thyroid disorders among Chinese adults: a nationwide cross-sectional study.Front Endocrinol (Lausanne). 2023 Apr 21;14:1158013. doi: 10.3389/fendo.2023.1158013. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37152970 Free PMC article.
-
Dynamic status of metabolically healthy overweight/obesity and metabolically unhealthy and normal weight and the risk of type 2 diabetes mellitus: A cohort study of a rural adult Chinese population.Obes Res Clin Pract. 2018 Jan-Feb;12(1):61-71. doi: 10.1016/j.orcp.2017.10.005. Epub 2017 Oct 31. Obes Res Clin Pract. 2018. PMID: 29100915
-
Risk of incident chronic kidney disease in metabolically healthy obesity and metabolically unhealthy normal weight: A systematic review and meta-analysis.Obes Rev. 2024 Feb;25(2):e13656. doi: 10.1111/obr.13656. Epub 2023 Oct 30. Obes Rev. 2024. PMID: 37904643
-
The Association Between Metabolic Status and Risk of Cancer Among Patients With Obesity: Metabolically Healthy Obesity vs. Metabolically Unhealthy Obesity.Front Nutr. 2022 Feb 25;9:783660. doi: 10.3389/fnut.2022.783660. eCollection 2022. Front Nutr. 2022. PMID: 35284439 Free PMC article.
Cited by
-
Sex disparity in the association between metabolic-anthropometric phenotypes and risk of obesity-related cancer: a prospective cohort study.BMC Med. 2024 Sep 2;22(1):355. doi: 10.1186/s12916-024-03592-9. BMC Med. 2024. PMID: 39218868 Free PMC article.
-
Associations of accelerated biological aging and metabolic heterogeneity of obesity with rheumatoid arthritis: a prospective cohort study.Clin Rheumatol. 2024 Dec;43(12):3615-3623. doi: 10.1007/s10067-024-07167-0. Epub 2024 Oct 5. Clin Rheumatol. 2024. PMID: 39367918
-
Associations between metabolic overweight/obesity phenotypes and mortality risk among patients with chronic heart failure.Front Endocrinol (Lausanne). 2024 Sep 20;15:1445395. doi: 10.3389/fendo.2024.1445395. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39371927 Free PMC article.
-
Obesity and lung cancer-a narrative review.J Thorac Dis. 2023 May 30;15(5):2806-2823. doi: 10.21037/jtd-22-1835. Epub 2023 May 8. J Thorac Dis. 2023. PMID: 37324095 Free PMC article. Review.
-
The health and economic burden of rare endocrine disease: Often ignored, always important.J Glob Health. 2024 Dec 9;14:04249. doi: 10.7189/jogh.14.04249. J Glob Health. 2024. PMID: 39651662 Free PMC article.
References
-
- Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med. 2009;360(14):1418–1428. - PubMed
-
- Hospital Readmissions Reduction Program (HRRP). https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpat.... Accessed 4 April 2022.
-
- Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. - PubMed
-
- Huang J, Deng Y, Tin MS, et al. Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: a global analysis. Chest. 2022;161(4):1101–1111. - PubMed
LinkOut - more resources
Full Text Sources